Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 483

What a global tech arms race means for investors

It’s fair to say geopolitics is the most fraught it’s been in the last two decades.

The battle over energy between Russia and Europe has been dominating headlines, while more recently, Nancy Pelosi’s visit to Taiwan has set the US and China on a pathway of competitive escalation.

Semiconductors and tech independence play a critical role in US-China relations, and this cannot be resolved quickly given both countries are dependent on Taiwan – or specifically Taiwan Semiconductor Manufacturing Company (TSMC) – for the manufacture of leading-edge chips.

For some time now the US has prevented a small number of Chinese firms from accessing US-designed semiconductors and the equipment to make these chips where it was assumed this technology was being used for military purposes. As tensions between the two global superpowers soured further, we noted the tail risk was how far the US would push to more broadly limit China’s ability to innovate.

The US has indeed now taken a further step – introducing sweeping new controls that can limit exports to China of critical technology used to manufacture semiconductors.

Here’s what the US Department of Commerce said in an announcement regarding the move:

“The Department of Commerce’s Bureau of Industry and Security (BIS) is implementing a series of targeted updates to its export controls as part of BIS’s ongoing efforts to protect U.S. national security and foreign policy interests. These updates will restrict the People’s Republic of China’s (PRC’s) ability to both purchase and manufacture certain high-end chips.”

The details of the new controls show the US is targeting GPU, CPU and DRAM (memory) chips designed in the last five years and the equipment to make these chips, as well as NAND (memory) chips designed over the last three years. There are also specific rules limiting China’s ability to import certain AI chips widely used in datacentres and critical to many modern consumer applications.

While this policy stops short of a blanket ban, the goal is to restrict China’s access to chips and other technology related to advanced AI and super-computing as these have military applications.

What are the consequences of this move?

Most leading-edge semiconductor chips essential for high performance computing are designed by US or European companies such as Nvidia, AMD, Broadcom, Marvell, Intel. But the chips are not necessarily manufactured by these companies.

In fact, at the leading-edge these semiconductor chips are almost entirely manufactured by TSMC.

TSMC has actively retained its leading-edge chip capacity at home in Taiwan, a strategy referred to as the ‘silicon shield’. But what’s interesting here is that more than half of the equipment used to manufacture globally critical chips comes from the US, with the rest from Europe and Japan.

If Europe and Japan choose to follow the US’ lead, it places China in an extremely challenging position. Inability to access chips and furthermore the equipment used to manufacture these chips will meaningfully hamstring not only China’s ability to keep up with tech developments in the West, but also hinder China’s capacity to develop tech independence.

At first blush, the development of Chinese hyperscalers such as Tencent, Alibaba and Baidu could be impacted as the bulk of datacentre spend is AI-centric even for current consumer use around content creation, search and natural language programming.

Chinese EVs may also see progress curbed relative to Western peers as ADAS chips (advanced driver assistance systems) could be affected. At this stage restrictions on handset chips appears unlikely given the limited crossover with military applications. The language framing these restrictions, which are some of the most comprehensive we’ve seen to date, suggests these restrictions could be part of a rolling series.

Much remains up in the air

How rigorously will the US enforce these license approvals? Will Europe and Japan follow suit? How might the US expand export restrictions or worse initiate bans? Will China retaliate, and on a longer-term basis can China develop this technology internally?

China could choose to respond in a targeted fashion directed at high profile US brands with large profit pools in China such as Apple, Tesla, Nike and Estee Lauder amongst others. China could limit US access to strategic markets that it dominates such as rare earths in the EV battery supply chain.

If the US were to escalate further via an embargo on all investment in China, it would be an extremely negative outcome, not just for China but for the global economy and asset markets.

At this stage we still consider a Taiwan ‘hot war’ scenario relatively remote given the US and China’s co-dependence on Taiwan, or should we say TSMC. For now, China and the US are critically aligned in maintaining a stable Taiwan for the sake of their respective economic stability.

Uncovering winners in an evolving geopolitical landscape and new market regime

With regards to the escalating tensions between the US and China, we think it is critical investors monitor developments closely and consider global vulnerabilities should China choose to retaliate.

When it comes to the broader global macroeconomic environment, stagflation (high inflation combined with lower economic growth) remains our base case, and with a mild recession, as China has the potential to loosen monetary policy even as the West is tightening.

The US economy, however, bears close watching as the risk of a ‘hard landing’ is rising. If the Fed over-tightens to control inflation it risks dragging the US into a deeper recession.

The year so far has been challenging for global equities. Economic data is rapidly weakening, consensus estimates on our analysis are broadly still too high and equity inflows have been slow to reverse. Despite this, opportunities exist. The likely winners in today’s world look very different to the winners of yesteryear.

The QE-led growth/long duration regime that dominated the post-2008 investing period is transitioning to a regime that will see policy makers lean on fiscal stimulus to prop up economic activity. In the near term this stimulus will focus on the cost-of-living crisis (as already seen in the UK and Europe), but over the longer term it will focus on investment around decarbonisation, infrastructure and security (defence and supply chains).

The US’ Inflation Reduction Act is a great example of this trend. It supports $370 billion worth of investment in energy security and climate change with almost one-quarter of the programme dedicated to re-shoring solar, wind and battery production in the US.

In global markets, there are great opportunities for investors to position for these trends.

While the range of outcomes around inflation and global economic activity remain high, our view is that defensive exposures and beneficiaries of longer-term investment trends can outperform.

Examples of these exposures in Antipodes’ portfolios include:

  • Merck (NYSE:MRK): lower drug pricing risk and manageable patent risk relative to peers, and a diversified earnings stream from long duration businesses including vaccines and animal health.
  • Gilead (NASDAQ:GILD): HIV patent cliff pushed out while new treatments are developed to extend dominance, and an under-appreciated pipeline.
  • SAP (NYSE:SAP) and Oracle (NYSE:ORCL): dominate the ERP/enterprise resource planning market (general ledger and accounting software) where transitioning this mission-critical software to the cloud has become a priority in our post-COVID hybrid work environment, and this transition is continuing in even a tougher economic environment.
  • Diageo (LON:DGE): leading spirits business with 5% share of total alcohol consumption globally that is taking market share in categories that are growing and is facing lower inflationary pressures than other defensive parts of the market such as consumer staples.

Thinking outside the unipolar lens

Finally, when looking at geographic diversification, global investors may be well served by considering the world through a multipolar lens.

Emerging markets are valued at around a 35% discount to developed markets – one of the largest discounts in the last 20 years. But while EM hasn’t been a popular asset class in recent times, we have been increasing increase exposure to emerging countries such as Indonesia, Mexico and Brazil which are beneficiaries of the evolving multipolar geopolitical landscape, and where valuations and growth rates are attractive.

Source: Antipodes, Factset

Indonesia, for example, is benefiting from structural reform following almost a decade of political stability. It has a large and young population, and hurdles around labour laws and infrastructure are being removed. It is a beneficiary of higher commodity prices and can also benefit from diversifying manufacturing bases that are heavily centred in China.

Likewise, Mexico can be a beneficiary of on-shoring and near-shoring manufacturing, which has become a major initiative for US corporations.

In Brazil, the recent passing of the election reduces political risk and balancing the cabinet with more centrist candidates could see President Lula achieve an attractive balance between spending and reform.

Further, currency and bond markets in these countries are showing a high degree of resilience due to much tighter long-term fiscal and monetary policy settings versus many Western equivalents.

So, while we are witnessing one of the most complex environments investors have had to navigate in decades, it’s an environment that has also presented pragmatic global investors with great opportunities.

 

Alison Savas is a Client Portfolio Manager at Antipodes Partners. Antipodes is affiliated with Pinnacle Investment Management, a sponsor of Firstlinks. This article is general information and does not consider the circumstances of any investor.

For more articles and papers from Pinnacle and its affiliates, click here.

 

banner

Most viewed in recent weeks

Vale Graham Hand

It’s with heavy hearts that we announce Firstlinks’ co-founder and former Managing Editor, Graham Hand, has died aged 66. Graham was a legendary figure in the finance industry and here are three tributes to him.

Australian stocks will crush housing over the next decade, one year on

Last year, I wrote an article suggesting returns from ASX stocks would trample those from housing over the next decade. One year later, this is an update on how that forecast is going and what's changed since.

Avoiding wealth transfer pitfalls

Australia is in the early throes of an intergenerational wealth transfer worth an estimated $3.5 trillion. Here's a case study highlighting some of the challenges with transferring wealth between generations.

Taxpayers betrayed by Future Fund debacle

The Future Fund's original purpose was to meet the unfunded liabilities of Commonwealth defined benefit schemes. These liabilities have ballooned to an estimated $290 billion and taxpayers continue to be treated like fools.

Australia’s shameful super gap

ASFA provides a key guide for how much you will need to live on in retirement. Unfortunately it has many deficiencies, and the averages don't tell the full story of the growing gender superannuation gap.

Looking beyond banks for dividend income

The Big Four banks have had an extraordinary run and it’s left income investors with a conundrum: to stick with them even though they now offer relatively low dividend yields and limited growth prospects or to look elsewhere.

Latest Updates

Investment strategies

9 lessons from 2024

Key lessons include expensive stocks can always get more expensive, Bitcoin is our tulip mania, follow the smart money, the young are coming with pitchforks on housing, and the importance of staying invested.

Investment strategies

Time to announce the X-factor for 2024

What is the X-factor - the largely unexpected influence that wasn’t thought about when the year began but came from left field to have powerful effects on investment returns - for 2024? It's time to select the winner.

Shares

Australian shares struggle as 2020s reach halfway point

It’s halfway through the 2020s decade and time to get a scorecheck on the Australian stock market. The picture isn't pretty as Aussie shares are having a below-average decade so far, though history shows that all is not lost.

Shares

Is FOMO overruling investment basics?

Four years ago, we introduced our 'bubbles' chart to show how the market had become concentrated in one type of stock and one view of the future. This looks at what, if anything, has changed, and what it means for investors.

Shares

Is Medibank Private a bargain?

Regulatory tensions have weighed on Medibank's share price though it's unlikely that the government will step in and prop up private hospitals. This creates an opportunity to invest in Australia’s largest health insurer.

Shares

Negative correlations, positive allocations

A nascent theme today is that the inverse correlation between bonds and stocks has returned as inflation and economic growth moderate. This broadens the potential for risk-adjusted returns in multi-asset portfolios.

Retirement

The secret to a good retirement

An Australian anthropologist studying Japanese seniors has come to a counter-intuitive conclusion to what makes for a great retirement: she suggests the seeds may be found in how we approach our working years.

Sponsors

Alliances

© 2024 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.